Drug Database
CO

COVID-19 vaccine (ARCT 154 / Kostaive / ARCT154)

✓ Approved

Arcturus Therapeutics, Inc. · 疫苗 · 疫苗

什么是 COVID-19 vaccine?

COVID-19 vaccine 是一种疫苗,由Arcturus Therapeutics, Inc.研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intramuscular (IM) Injection。

药物档案

商品名ARCT 154, Kostaive, ARCT154
公司Arcturus Therapeutics, Inc.
药物类别疫苗
给药途径Injectable (Others), Intramuscular (IM) Injection
状态Approved

治疗适应症

COVID-19 vaccine 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsCOVID-19✓ Approved

相关研究文献

PubMedWellcome open research2026-11-19

Did the emergence of the Omicron variant impact the COVID-19 vaccine acceptance in the Arab world? A Twitter-based sentiment analysis.

Dimashkieh Chehab Nada N

Low vaccine acceptance constitutes a major obstacle for achieving herd immunity against coronavirus disease 2019 (COVID-19). Data on COVID-19 show a significant rise in the number of cumulative cases in Arab countries where vaccine uptake is lower than the uptake at the global level for the 2021-2022 period. The aim of this study is to analyze sentiments related to vaccine acceptance before and after the emergence of the COVID-19 Omicron variant in the Arab-speaking world. Tweets were collected before and after the Omicron emergence period in the Arab-speaking world using Python-enabled CAMeL Tools (Arabic Natural Language Processing toolkit) libraries. A sentiment analysis on COVID-19 vaccines using Arabic hashtags and a sentiment analysis by city were conducted. Two data sets pre-Omicron and post-Omicron tweets exhibited a difference in sentiments marking a shift towards less negativity and more neutrality. Sentiments by city showed most tweets in both periods coming from Riyadh and Jeddah in Saudi-Arabia, and from Salt in Jordan. Despite the limitations of the study, the change in sentiments detected by the study may suggest more vaccine acceptance which raises some hope and perhaps a higher vaccine uptake in the future. The sentiments by city findings may help in the design of future research.

PMID 43053887
阅读全文 →
PubMedNPJ vaccines2026-11-19

Efficacy, safety, and biodistribution of intranasally delivered adenoviral COVID-19 vaccine in hamsters.

Laham-Karam N N, Mäkinen P P, Koivulehto E E, Gurzeler E E et al.

Coronavirus disease 2019 (COVID-19) continues to cause outbreaks around the world despite the vast COVID-19 vaccination programs. Thus, it is important to continue developing better vaccines to protect vulnerable populations. Here, we studied the efficacy, safety, persistence and biodistribution of an adenovirus-based COVID-19 vaccine delivered intranasally. Our results confirmed that mucosal delivery leads to effective protection against infection in hamsters. A comparative study of different adenoviral vectors demonstrated that specifically Ad5-S-3M, expressing the SARS-CoV-2 spike glycoprotein ectodomain with inclusion of three common receptor binding domain mutations, induced a robust humoral immune response and effectively protected hamsters from SARS-CoV-2 infection. In addition, longitudinal analysis of vaccinated hamsters' tissues demonstrated durable vaccine transgene expression and persistent vector DNA in the nasal turbinates. This persistence may be beneficial in increasing the duration of immunity. Expression of the S-3M did not cause any aberrant changes in the hamster tissues and resulted in very few changes in cellular mRNA expression in target tissues. Safety and biodistribution assessment demonstrated restricted non-target tissue distribution of intranasally delivered vector and no significant changes in clinical blood chemistry, underlining the safety of the vaccine. These results further support that intranasal delivery is a promising approach for mucosal vaccine administration against respiratory infection pathogens and extend our knowledge of Adeno-vector persistence.

PMID 43052363
阅读全文 →
PubMedPopulation health management2026-11-19

Disparities During the COVID-19 Pandemic in SARS-CoV-2 Testing Increased After a Federal Government's At-Home Testing Distribution Program Compared with Before in a U.S. Urban Setting.

Schenkel Penelope P, Mueller Alexandra K AK, Wagner Duchen Jessica J, Perin Jamie J et al.

Diagnostic testing is essential for controlling the transmission of infectious diseases. During the COVID-19 pandemic, testing became widely available in the United States. However, the association between a federal at-home COVID-19 rapid antigen test distribution program and sociodemographics and COVID-19 testing remains unknown. This secondary analysis aims to (1) assess the association between the federal at-home testing program and testing uptake and (2) examine associations, including interactions with the testing program, between sociodemographic characteristics, testing experience, and COVID-19 testing. We analyzed baseline data collected from February 2021 to November 2022 in a randomized comparative effectiveness parent trial conducted in a mid-Atlantic U.S. city (N = 1859). Logistic regression models with robust standard errors were used. Overall, 79.9% (1486) of participants reported receiving a COVID-19 test. Exposure to the federal testing program (odds ratio [OR] = 2.25; 95% confidence interval [CI]: 1.61, 3.13), higher education (OR = 1.36; 95% CI: 1.02, 1.80), private health insurance (OR = 2.03; 95% CI: 1.41, 2.92), higher household income (OR = 1.49; 95% CI: 1.06, 2.09), and ease of testing access (OR = 1.40; 95% CI: 1.04, 1.87) were significantly associated with testing. After adjustment, private insurance (adjusted OR [aOR] = 1.61; 95% CI: 1.12, 2.31) and higher income (aOR = 1.50; 95% CI: 1.12, 2.02) remained associated with testing. The adjusted odds of COVID-19 testing were 2-fold higher (aOR = 2.21; 95% CI: 1.21, 4.04) for high-income (vs. low-income) households during the federal at-home COVID-19 rapid antigen testing program than before its implementation. Disparities in COVID-19 testing by socioeconomic status increased during the federal testing program compared with the period before its implementation. Ensuring equitable access to diagnostic testing remains critical for an effective public health response.

PMID 43053486
阅读全文 →
PubMedAJE advances : research in epidemiology2026-11-19

Did in-person work contribute to racial disparities in COVID-19 mortality? Evidence from a mediation analysis using case-control and population-based cohort designs.

Gebreegziabher Elisabeth E, Porse Charsey C, Lee Gar-Wei GW, Frederick Matthew M et al.

We examined whether physical presence at the workplace contributed to racial disparities in COVID-19 mortality among working-age Californians. Using a case-control design, we compared all COVID-19 deaths (n = 4838) and non-COVID-19 deaths (n = 21 453) in California between January 2020 and March 2021, among decedents aged 18-64 confirmed to be working based on employment records. Workplace presence was defined by occupation using a job-exposure matrix. Logistic regression assessed links between racial/ethnic identity, workplace presence, and COVID-19 mortality. These associations were also evaluated in a population-based cohort using Current Population Survey data. Mediation analysis was conducted using the CAUSALMED procedure. Black, Indigenous, and other People of Color (BIPOC) had 39% higher odds of working in roles requiring physical presence compared to white workers (OR = 1.39, 95% CI: 1.30-1.49), and over 4 times higher odds of dying from COVID-19 (OR = 4.34, 95% CI: 3.93-4.79). Physical presence increased COVID-19 mortality risk (OR = 1.22, 95% CI: 1.11-1.33) but did not meaningfully mediate the relationship between BIPOC status and mortality (natural direct effect: OR = 4.29, 95% CI: 3.87-4.73; natural indirect effect: OR = 1.01, 95% CI: 1.00-1.02). Findings highlight occupational segregation and the elevated risks faced by essential workers but suggest that racial disparities in mortality are largely driven by structural factors beyond exposure opportunities associated with physical presence at the workplace.

PMID 43053793
阅读全文 →
PubMedPulmonology2026-11-19

Nebulized interferon-β1a (SNG001) in COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials.

Qin Jinlv J, Wang Guizuo G, Han Dong D

This systematic review and meta-analysis aimed to determine the efficacy of nebulised interferon-β1a (SNG001) in patients with Coronavirus disease-2019 (COVID-19). A systematic search was conducted across PubMed, Embase, Cochrane Library, and clinicaltrials.gov, without language restrictions. Studies were searched up to November 2025. Randomised controlled trials (RCTs) on treatment of COVID-19 with SNG001, compared with placebo or standard of care, were reviewed. Data were analysed using the RevMan Version 5.1 (The Cochrane Collaboration). Pooled risk ratios (RRs) with 95% confidence intervals (CIs) were calculated for dichotomous outcomes. Four RCTs (enrolling 1055 participants) met the inclusion criteria. The proportion of patients with hospitalisations (data extracted from two RCTs) (RR 0.16, 95% CI 0.03 to 0.88), and serious adverse events (RR 0.65, 95% CI 0.47 to 0.90) were significantly fewer in SNG001 groups. There was no statistically significant difference in all-cause mortality (RR 0.72, 95% CI 0.37 to 1.39), patients non-recovery at day 28 (RR 0.87, 95% CI 0.65 to 1.17), and adverse event (RR 0.97, 95% CI 0.90 to 1.04) between the two groups. Nebulised SNG001 was safe and associated with a reduction in COVID-19-related hospital admission. SNG001 shows a potential benefit for outpatients with COVID-19, but it requires larger clinical trials for future validations, particularly in vaccinated and previously infected populations.

PMID 43053745
阅读全文 →
PubMedBMC infectious diseases2026-11-19

Real-world effectiveness of early nirmatrelvir/ritonavir initiation after COVID-19 diagnosis in outpatient setting against severe illness, hospitalization, death, and long COVID in N3C.

Makkar Steve R SR, Hansen Kristen K, Yadaw Arjun S AS, Tripler Therese T et al.

COVID-19 has placed a monumental burden on the health care system globally. Although no longer a public health emergency, there is still a pressing need for effective treatments that prevent adverse outcomes associated with this disease. Nirmatrelvir/ritonavir (NMV-R) is a promising and potentially effective antiviral, which until recently was under emergency use authorization. Our objective was to evaluate the real-world effectiveness of NMV-R in preventing severe illness, hospitalization, death and long-COVID in a large nationwide cohort of outpatients with COVID-19. Population-based retrospective cohort study of patients with a SARS-CoV-2 positive test or diagnosis (index) date between December 2021 and February 2023 within the National COVID Cohort Collaborative (N3C), with at least one risk factor for severe COVID-19, no evidence of contraindicated medical conditions or medication use, and no hospital or emergency department visit or death within 24 hours of eligibility. We emulated a sequence of target trials beginning on each of the first five days of diagnosis with COVID-19. We identified 921,034 eligible person-trials (each representing a patient's eligibility at a given diagnosis day across sequential emulated trials), of which 77,449 were initiators and 846,585 were non-initiators of NMV-R treatment. NMV-R Initiators were matched to non-initiators in each trial. The marginal hazard ratio between initiators and non-initiators was estimated for four acute outcomes: severe illness, hospitalization or death, hospitalization, and death; and the post-COVID condition or long COVID. Of 921,034 eligible "person-trials", 74,449 were initiators and 846,585 were non-initiators of NMV-R treatment. Pooled across trials, the hazard for severe illness (HR: 0.76, 95% CI: 0.71 to 0.81), hospitalization or death (HR: 0.50, 95% CI: 0.44 to 0.57), hospitalization (sdHR: 0.52, 95% CI: 0.46 to 0.60), death (HR: 0.33, 95% CI: 0.21 to 0.51), and long-COVID (sdHR: 0.85, 95% CI: 0.77 to 0.95) were significantly lower among NMV-R initiators compared to non-initiators. Results further indicated larger associations between NMV-R and reduced risk of both acute and post-acute outcomes with early versus delayed NMV-R treatment initiation, and among unvaccinated versus vaccinated patient subgroups. NMV-R is overall effective at preventing the risk of severe acute outcomes including hospitalization and death, as well as long COVID. Results were robust across multiple sensitivity considerations. Not applicable.

PMID 43052808
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多COVID-19 vaccine